Skip to main content
. 2020 Nov 26;16:460. doi: 10.1186/s12917-020-02664-1

Table 2.

Assessment of reporting quality of included studies

Content and Subject Item Description Total pre-ARRIVE post-ARRIVE χ2 value P value
items assessed as “yes” items assessed as “yes” items assessed as “yes”
N % N % N %
TITLE
1 Provide as accurate and concise a description of the content of the article as possible. 4241 97.7 2196 97.1 2045 98.3 6.25 0.012
ABSTRACT
2 Provide an accurate summary of the background, research objectives (including details of the species or strain of animal used), key methods, principal findings, and conclusions of the study 4117 94.8 2084 92.2 2033 97.7 67.25 < 0.001
INTRODUCTION
 Background 3a Include sufficient scientific background (including relevant references to previous work) to understand the motivation and context for the study, and explain the experimental approach and rationale. 4071 93.8 2057 91.0 2014 96.8 62.36 < 0.001
3b Explain how and why the animal species and model being used can address the scientific objectives and, where appropriate, the study’s relevance to human biology. 1609 37.1 737 32.6 872 41.9 40.24 < 0.001
 Objectives 4 Clearly describe the primary and any secondary objectives of the study, or specific hypotheses being tested. 4248 97.8 2198 97.2 2050 98.5 8.60 0.003
METHODS
 Ethical statement 5 Indicate the nature of the ethical review permissions, relevant licenses (e.g. Animal [Scientific Procedures] Act 1986), and national or institutional guidelines for the care and use of animals, that cover the research. 286 6.59 125 5.53 161 7.74 8.59 0.003
 Study design 6a For each experiment, give brief details of the study design, including: the number of experimental and control groups. 3741 86.2 1893 83.7 1848 88.8 23.44 < 0.001
6b For each experiment, give brief details of the study design, including: any steps taken to minimise the effects of subjective bias when allocating animals to treatment (e.g., randomisation procedure) and when assessing results (e.g., if done, describe who was blinded and when). 3961 91.2 2034 90.0 1927 92.6 9.43 0.002
6c For each experiment, give brief details of the study design, including: the experimental unit (e.g. a single animal, group, or cage of animals). 4312 99.3 2245 99.3 2067 99.3 0.02 0.890
6d For each experiment, give brief details of the study design, including: A time-line diagram or flow chart can be useful to illustrate how complex study designs were carried out. 63 1.45 15 0.66 48 2.31 20.46 < 0.001
 Experimental procedures 7a For each experiment and each experimental group, including controls, provide precise details of all procedures carried out. For example: How (e.g., drug formulation and dose, site and route of administration, anaesthesia and analgesia used [including monitoring], surgical procedure, method of euthanasia). Provide details of any specialist equipment used, including supplier(s). 4172 96.1 2165 95.8 2007 96.4 1.37 0.242
7b For each experiment and each experimental group, including controls, provide precise details of all procedures carried out. For example: When (e.g., time of day). 269 6.20 214 9.46 55 2.64 86.78 < 0.001
7c For each experiment and each experimental group, including controls, provide precise details of all procedures carried out. For example: Where (e.g., home cage, laboratory, water maze). 513 11.8 309 13.7 204 9.80 15.53 < 0.001
7d For each experiment and each experimental group, including controls, provide precise details of all procedures carried out. For example: Why (e.g., rationale for choice of specific anaesthetic, route of administration, drug dose used). 1631 37.6 806 35.7 825 39.6 7.38 0.007
 Experimental animals 8a Provide details of the animals used, including species, strain, sex, developmental stage (e.g., mean or median age plus age range), and weight (e.g., mean or median weight plus weight range). 4162 95.9 2160 95.5 2002 96.2 1.23 0.268
8b Provide further relevant information such as the source of animals, international strain nomenclature, genetic modification status (e.g. knock-out or transgenic), genotype, health/immune status, drug- or testnaive, previous procedures, etc. 3785 87.2 1909 84.4 1876 90.2 31.68 < 0.001
 Housing and husbandry 9a Housing (e.g., type of facility, specific pathogen free (SPF); type of cage or housing; bedding material; number of cage companions; tank shape and material etc. for fish). 1022 23.5 409 1819 613 29.5 77.81 < 0.001
9b Husbandry conditions (e.g., breeding programme, light/dark cycle, temperature, quality of water etc. for fish, type of food, access to food and water, environmental enrichment). 928 21.4 338 15.0 590 28.4 115.83 < 0.001
9c Welfare-related assessments and interventions that were carried out before, during, or after the experiment. 147 3.39 77 3.41 70 3.36 0.01 0.939
 Sample size 10a Specify the total number of animals used in each experiment and the number of animals in each experimental group. 3440 79.2 1728 76.4 1712 82.3 22.47 < 0.001
10b Explain how the number of animals was decided. Provide details of any sample size calculation used. 1 0.02 0 0.00 1 0.05 1.09 0.297
10c Indicate the number of independent replications of each experiment, if relevant. 6 0.14 4 0.18 2 0.10 0.51 0.474
 Allocating animals to experimental groups 11a Give full details of how animals were allocated to experimental groups, including randomization or matching if done. 522 12.0 208 9.20 314 15. 1 35.54 < 0.001
11b Describe the order in which the animals in the different experimental groups were treated and assessed. 4070 93.7 2100 92.9 1970 94.7 5.89 0.015
 Experimental outcomes 12 Clearly define the primary and secondary experimental outcomes assessed (e.g., cell death, molecular markers, behavioral changes). 4071 93.8 2098 92.8 1973 94.8 7.55 0.006
 Statistical methods 13a Provide details of the statistical methods used for each analysis. 3585 82.6 1677 74.2 1908 91.7 230.97 < 0.001
13b Specify the unit of analysis for each dataset (e.g. single animal, group of animals, single neuron). 2840 65.4 1287 56.9 1553 74.6 150.14 < 0.001
13c Describe any methods used to assess whether the data met the assumptions of the statistical approach. 662 15.3 284 12.6 378 18.2 26.33 < 0.001
RESULTS
 Baseline data 14 For each experimental group, report relevant characteristics and health status of animals (e.g., weight, microbiological status, and drug- or test-naı¨ve) before treatment or testing (this information can often be tabulated). 223 5.14 87 3.85 136 6.54 16.06 < 0.001
 Numbers analysed 15a Report the number of animals in each group included in each analysis. Report absolute numbers (e.g.10/20, not 50%) 3023 69.6 1546 68.4 1477 71.0 3.46 0.063
15b If any animals or data were not included in the analysis, explain why. 3213 74.0 1661 73.5 1552 74.6 0.70 0.402
 Outcomes and estimation 16 Report the results for each analysis carried out, with a measure of precision (e.g, standard error or confidence interval). 3811 87.8 1918 84.8 1893 91.0 38.01 < 0.001
 Adverse events 17a Give details of all important adverse events in each experimental group. 64 1.47 21 0.93 43 2.07 9.66 0.002
17b Describe any modifications to the experimental protocols made to reduce adverse events. 1 0.02 1 0.04 0 0.00 0.92 0.337
DISCUSSION
 Interpretation/scientific implications 18a Interpret the results, taking into account the study objectives and hypotheses, current theory, and other relevant studies in the literature. 4157 95.7 2143 94.8 2014 96.8 10.62 0.001
18b Comment on the study limitations including any potential sources of bias, any limitations of the animal model, and the imprecision associated with the results. 228 5.25 103 4.56 125 6.01 4.59 0.032
18c Describe any implications of your experimental methods or findings for the replacement, refinement, or reduction (the 3Rs) of the use of animals in research. 15 0.35 4 0.18 11 0.53 3.89 0.048
 Generalisability/translation 19 Comment on whether, and how, the findings of this study are likely to translate to other species or systems, including any relevance to human biology. 281 6.47 134 5.93 147 7.06 2.32 0.128
 Funding 20 List all funding sources (including grant number) and the role of the funder(s) in the study. 47 1.08 15 0.66 32 1.54 7.74 0.005